4//SEC Filing
McClellan Michael James 4
Accession 0001209191-19-017232
CIK 0000818686other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 7:18 AM ET
Size
5.9 KB
Accession
0001209191-19-017232
Insider Transaction Report
Form 4
McClellan Michael James
EVP, Chief Financial Officer
Transactions
- Award
Restricted Share Units
2019-03-04+50,746→ 50,746 total→ Ordinary Shares (50,746 underlying)
Footnotes (3)
- [F1]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F2]Restricted share units were granted on March 4, 2019, with 16,915 vesting on each of March 4, 2021 and March 4, 2022 and 16,916 vesting on March 4, 2023.
- [F3]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001721544
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 7:18 AM ET
- Size
- 5.9 KB